Economic feasibility study and reimbursement rules - Illustrated by a concrete example;Oslash;konomiske konsekvensberegninger og tilskudsregler - Belyst ved et eksempel

Ugeskrift for Laeger

Volumn 170, Issue 8, 2008, Pages 651-654

  Keiding, Hans ^a   Færgeman, Ole ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FEASIBILITY STUDY; HUMAN; REIMBURSEMENT;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG COSTS; FEASIBILITY STUDIES; HUMANS; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS;

EID: 41449100491     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78.
3. Jönsson B, Johannesson M, Kjekshus J et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-7.
4. Johannesson M, Jönsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholestorol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6.
5. Goa KL, Barradell LB, McTavish D. Simvastatin. Pharmacoeconomics 1997;11:89-110.
6. Drummond M, McGuire A. Economic evaluation in health care, merging theory with practice. New York: Oxford University Press, 2001.